Bio-Rad Laboratories, Inc.
BIONYSEHealthcare● Active
$295.07
+$0.75(+0.25%)
Market Cap$8.0B
P/E Ratio—
52W High$343.12
52W Low$218.14
Bio-Rad Laboratories, Inc. (BIO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BIO · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.58B | $2.57B | $2.67B | $2.80B | $2.92B |
| Cost of Revenue | $1.24B | $1.19B | $1.24B | $1.23B | $1.28B |
| Gross Profit | $1.34B | $1.38B | $1.43B | $1.57B | $1.64B |
| Gross Margin %(computed) | 52.01% | 53.73% | 53.42% | 55.93% | 56.05% |
| Operating Expenses | |||||
| R&D Expenses | $0.26B | $0.30B | $0.25B | $0.26B | $0.26B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $1.08B | $1.11B | $1.09B | $1.08B | $1.14B |
| Operating Income | $0.27B | $0.27B | $0.34B | $0.48B | $0.50B |
| Operating Margin %(computed) | 10.47% | 10.48% | 12.65% | 17.22% | 17.12% |
| Interest Income | $0.10B | $0.08B | $0.10B | $0.06B | $0.02B |
| Interest Expense | $0.05B | $0.05B | $0.05B | $0.04B | $0.00B |
| Income Before Tax | $1.00B | ($2.34B) | ($0.85B) | ($4.70B) | $5.45B |
| Income Tax Expense | $0.24B | ($0.50B) | ($0.21B) | ($1.08B) | $1.19B |
| Net Income | $0.76B | ($1.84B) | ($0.64B) | ($3.63B) | $4.25B |
| Net Margin %(computed) | 29.42% | -71.86% | -23.86% | -129.45% | 145.57% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $27.87 | $-65.36 | $-21.82 | $-121.79 | $142.61 |
| Wtd Avg Shares | 0.03B | 0.03B | 0.03B | 0.03B | 0.03B |
| EBITDA | $0.48B | ($2.14B) | ($0.65B) | ($4.49B) | $5.59B |
| EBITDA Margin %(computed) | 18.42% | -83.46% | -24.51% | -160.19% | 191.21% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Bio-Rad Laboratories, Inc. data
About Bio-Rad Laboratories, Inc. (BIO) Income Statement
Bio-Rad Laboratories, Inc. (BIO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, BIO reported revenue of $2.58B, gross profit of $1.34B (gross margin 52.01%), and net income of $0.76B — a net profit margin of 29.42%.
Frequently asked questions
BIO · 4 questionsBio-Rad Laboratories, Inc. (BIO) reported revenue of $2.58B for 2025, up 0.7% year-over-year.
BIO revenueBIO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08